Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 4;5(4):235-250.
doi: 10.5492/wjccm.v5.i4.235.

Plasma-Lyte 148: A clinical review

Laurence Weinberg  1 , Neil Collins  1 , Kiara Van Mourik  1 , Chong Tan  1 , Rinaldo Bellomo  1
Affiliations

Plasma-Lyte 148: A clinical review

Laurence Weinberg et al. World J Crit Care Med. .

Abstract

Aim: To outline the physiochemical properties and specific clinical uses of Plasma-Lyte 148 as choice of solution for fluid intervention in critical illness, surgery and perioperative medicine.

Methods: We performed an electronic literature search from Medline and PubMed (via Ovid), anesthesia and pharmacology textbooks, and online sources including studies that compared Plasma-Lyte 148 to other crystalloid solutions. The following keywords were used: "surgery", "anaesthesia", "anesthesia", "anesthesiology", "anaesthesiology", "fluids", "fluid therapy", "crystalloid", "saline", "plasma-Lyte", "plasmalyte", "hartmann's", "ringers" "acetate", "gluconate", "malate", "lactate". All relevant articles were accessed in full. We summarized the data and reported the data in tables and text.

Results: We retrieved 104 articles relevant to the choice of Plasma-Lyte 148 for fluid intervention in critical illness, surgery and perioperative medicine. We analyzed the data and reported the results in tables and text.

Conclusion: Plasma-Lyte 148 is an isotonic, buffered intravenous crystalloid solution with a physiochemical composition that closely reflects human plasma. Emerging data supports the use of buffered crystalloid solutions in preference to saline in improving physicochemical outcomes. Further large randomized controlled trials assessing the comparative effectiveness of Plasma-Lyte 148 and other crystalloid solutions in measuring clinically important outcomes such as morbidity and mortality are needed.

Keywords: Acetate; Anesthesia; Crystalloids; Fluid therapy; Gluconate; Hartmann’s; Lactate; Plasma-Lyte; Ringers; Saline; Surgery.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Weinberg L is a recipient of research grants from Baxter Healthcare and is the Principle Investigator for the SPLIT-Major Surgery study. Bellomo R is a recipient of research grants from Baxter Healthcare and is a Principle Investigator for the SPLIT major surgery study. Baxter Healthcare is not involved in the design, collection of data, analyses, or interpretation of data from any Baxter sponsored fluid intervention study at the Austin Hospital. This review has been initiated and written independently of Baxter Healthcare or any other commercial institution.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Burdett E, Dushianthan A, Bennett-Guerrero E, Cro S, Gan TJ, Grocott MP, James MF, Mythen MG, O’Malley CM, Roche AM, et al. Perioperative buffered versus non-buffered fluid administration for surgery in adults. Cochrane Database Syst Rev. 2012;12:CD004089. - PubMed
    1. Product information. Plasma-Lyte 148 Replacement IV Infusion. [accessed. 2015. p. Jan 17]. Available from: http://www.baxterhealthcare.com.au/downloads/healthcare_professionals/cm....
    1. Y-Site Compatibility of Intravenous Drugs with Plasmalyte 148. Baxter Healthcare, 2015.
    1. Petraitiene R, Petraitis V, Witt JR, Durkin MM, Bacher JD, Wheat LJ, Walsh TJ. Galactomannan antigenemia after infusion of gluconate-containing Plasma-Lyte. J Clin Microbiol. 2011;49:4330–4332. - PMC - PubMed
    1. Hage CA, Reynolds JM, Durkin M, Wheat LJ, Knox KS. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol. 2007;45:676–677. - PMC - PubMed